Signal of Increased Risk of Major Cardiovascular Events and Cancer with Tofacitinib
EMA’s Pharmacovigilance Risk Assessment Committee concluded review of a safety signal
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy
The results of the ECOG-ACRIN EA1131 study in basal subtype triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Avapritinib, a kinase inhibitor, was evaluated in the EXPLORER and PATHFINDER studies
Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to EGFR TKI Therapy
Targeting unmet need in EGFR tyrosine kinase inhibitor resistant non-small cell lung cancer
High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
Pivotal results of the phase II, ZUMA-3 study
Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced Nasopharyngeal Carcinoma
Data support metronomic capecitabine as a potential adjuvant therapy for nasopharyngeal carcinoma
Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
A novel checkpoint inhibitors combination of nivolumab plus relatlimab validate dual LAG-3 and PD-1 inhibition
EMA Recommends Extension of Indications for Daratumumab
New indications concern the treatment of patients with multiple myeloma and light chain amyloidosis
EMA Recommends Extension of Indications for Blinatumomab
New indication concerns the treatment of paediatric patients with high-risk first relapsed Philadelphia chromosome negative CD19-positive B-precursor ALL
NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous than Previously Thought
Findings from the eNRGy1 global multicentre registry
Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma After Radical Surgery
The results of the CheckMate 274 study point to first immune checkpoint inhibitor prolonging the disease-free survival in this setting
FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC
FDA also approved the QIAGEN therascreen® KRAS RGQ PCR kit (tissue) and the Guardant360® CDx (plasma) as companion diagnostics